{"id":"W289544031","doi":"10.1200/jco.2014.32.15_suppl.5010","title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":231,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Nivolumab; Pazopanib; Sunitinib; Renal cell carcinoma; Internal medicine; Peripheral edema; Urology; Oncology; Gastroenterology; Surgery; Adverse effect; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006116833,0.0005318812,0.0008735046,0.0002555173,0.0002940202,0.000465793,0.0004517726,0.0003457288,0.001743661],"category_scores_gemma":[0.0003918772,0.0002645073,0.0005959728,0.0002931466,0.000318694,0.0003159443,0.0002754146,0.0009416384,0.0003596742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009543548,"about_ca_system_score_gemma":0.000977275,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001703313,"about_ca_topic_score_gemma":0.006899887,"domain_scores_codex":[0.9997762,0.00009310924,0.00001791782,0.00004250957,0.00002725754,0.00004301624],"domain_scores_gemma":[0.9998243,0.00002925949,0.0000311927,0.000009281154,0.000008887105,0.00009700096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.3839081,0.03794081,0.04693613,0.001693018,0.001432573,0.001771038,0.0007504435,0.00933415,0.1187585,0.0002526724,0.00574616,0.3914765],"study_design_scores_gemma":[0.1387257,0.6742598,0.1324086,0.0001337365,0.001136975,0.002167462,0.0002087687,0.007996665,0.02869448,0.000313294,0.01388824,0.00006615267],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971534,0.001108452,0.0001304273,0.0001035672,0.00001953855,0.0002761659,0.0001453597,0.00002063016,0.001042531],"genre_scores_gemma":[0.9972227,0.0007797982,0.0005832136,0.0001047903,0.00003454163,0.0001769062,0.0003148885,0.000007134181,0.0007760221],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001743661,"threshold_uncertainty_score":0.006924391,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07842517922211807,"score_gpt":0.3731375417796043,"score_spread":0.2947123625574863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}